Overall rank by patents
#48,648
of 49,997 tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 5 technology areas, recorded in grant years 2017–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61J (Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices ).
The verdict
According to USPTO PatentsView, Meditab ranks #48,648 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 5 technology areas.
USPTO PatentsView assignee plate
Corpus R48648 · US Corporation #48,648 · 5 grants
GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
Nearest grant-volume peer: Media Network Services AS (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Meditab Software · this assignee
26 score
3D Lighting… · lowest
7 score
What this shows Meditab's Innovation Score is 25.7/100 (18th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Meditab Software, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 60% of grants classified under A61J (Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices ). Peak complete grant year is 2017 (3 grants) versus a trough of 1 in 2018. By volume, Meditab sits between Media Network Services AS and Meljac.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Media Network Services AS
5 patents
Mediatechnologies LLC
5 patents
Medical Development Technologies S.A.
5 patents
Medicaltek Co., Ltd.
5 patents
Medskin Solutions DR. Suwelack AG
5 patents
MEG Group
5 patents
Meld Manufacturing Corporation
5 patents
Meljac
5 patents
Meditab Software, Inc.
5 patents
What this shows Meditab holds 5 patents at rank #48,586, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #48,586 in granted patent volume.
Other assignees with the most granted patents in Meditab's primary technology class.
Meditab's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
26 18th percentile higher than 18% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 3 | 60.0% |
| 2018 | 1 | 20.0% |
| 2020 | 1 | 20.0% |
Top 5 of 5 technology areas
Overall rank by patents
#48,648
of 49,997 tracked assignees
25.7 out of 100
What to do with this data
Meditab Software, Inc.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.